Literature DB >> 18398161

Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.

Cornelis J A Punt, Miriam Koopman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398161     DOI: 10.1200/JCO.2007.15.9640

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.

Authors:  Xun Bao; Jianmei Wu; Seongho Kim; Patricia LoRusso; Jing Li
Journal:  J Clin Pharmacol       Date:  2018-07-27       Impact factor: 3.126

Review 2.  Oral versus intravenous fluoropyrimidines for colorectal cancer.

Authors:  Fiona Chionh; David Lau; Yvonne Yeung; Timothy Price; Niall Tebbutt
Journal:  Cochrane Database Syst Rev       Date:  2017-07-28

3.  Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan.

Authors:  Saleh A Bakheet
Journal:  Oxid Med Cell Longev       Date:  2011-08-15       Impact factor: 6.543

4.  Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.

Authors:  Shouki Bazarbashi; Ali Aljubran; Ahmad Alzahrani; Ahmed Mohieldin; Hussein Soudy; Mohammed Shoukri
Journal:  Cancer Med       Date:  2015-07-24       Impact factor: 4.452

5.  Tumor biology and cancer therapy - an evolving relationship.

Authors:  Thomas Seufferlein; Johann Ahn; Denis Krndija; Ulrike Lother; Guido Adler; Götz von Wichert
Journal:  Cell Commun Signal       Date:  2009-08-13       Impact factor: 5.712

6.  A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

Authors:  E Vasile; G Masi; L Fornaro; S Cupini; F Loupakis; S Bursi; I Petrini; S Di Donato; I M Brunetti; S Ricci; A Antonuzzo; S Chiara; D Amoroso; M Andreuccetti; A Falcone
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.